Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...

The study will enrol 160 patients with IPF who have not previously received treatment.

Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the initiation of the AURA ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

While 80% of patients with pulmonary fibrosis find oxygen therapy beneficial, many face significant emotional and practical hurdles during initiation.

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey J. Swigris ...

In patients with CF, pre-transplant PH is associated with improved early post-transplant survival, but with poorer outcomes ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jeffrey J. Swigris ...

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...